Halozyme Secures European Injunction Against Merck's Keytruda SC…

Event summary

Halozyme won an injunction from the Dutch patent court halting Merck's manufacture and sale of Keytruda SC in eight European markets.
The court rejected Merck's arguments that Halozyme's MDASE patent EP622 is invalid.
Halozyme previously secured a similar injunction in Germany in December 2025.
The injunction does not affect the IV version of Keytruda, ensuring patient access.
Halozyme is also pursuing patent infringement claims against Merck in the U.S.

The big picture

Halozyme's victory in the Dutch court underscores the strategic importance of its MDASE technology in the subcutaneous drug delivery space. The injunction against Merck's Keytruda SC highlights the growing legal battles over patented drug delivery technologies, which are critical for reducing treatment burden and improving patient outcomes. Halozyme's ability to enforce its patents globally could set a precedent for other biotech companies with proprietary drug delivery technologies.

What we're watching

Legal Strategy: How Halozyme's global enforcement of its MDASE patents will impact Merck's Keytruda SC rollout in other markets.
Patent Validity: Whether Merck will appeal the Dutch court's decision and the potential outcomes of such appeals.
Market Impact: The pace at which Halozyme can monetize its patent victories through licensing or other agreements.